Bill Text: IL HR0103 | 2023-2024 | 103rd General Assembly | Introduced
Bill Title: Urges the Department of Human Services and the Governor's Opioid Overdose Prevention and Recovery Steering Committee to closely consider funding FDA-authorized PDTs to help patients who are struggling with substance use and opioid use disorders.
Spectrum: Partisan Bill (Democrat 1-0)
Status: (Passed) 2023-05-18 - Resolution Adopted [HR0103 Detail]
Download: Illinois-2023-HR0103-Introduced.html
| |||||||
| |||||||
| |||||||
1 | HOUSE RESOLUTION
| ||||||
2 | WHEREAS, The substance use and opioid use crises in | ||||||
3 | Illinois are responsible for historically high rates of | ||||||
4 | overdoses and overdose-related fatalities; and
| ||||||
5 | WHEREAS, According to the State's own opioid data, use and | ||||||
6 | misuse of opioids in Illinois also continues to have | ||||||
7 | substantial associated public health consequences, including | ||||||
8 | increased rates of infectious diseases such as hepatitis C and | ||||||
9 | HIV, lost productivity in the workplace, crime, neonatal | ||||||
10 | abstinence syndrome, and homelessness; and
| ||||||
11 | WHEREAS, Substance use and opioid use are often | ||||||
12 | detrimental to a person's mental health; access to innovative | ||||||
13 | and evidence-based treatments that address substance use and | ||||||
14 | opioid use can improve a patient's overall mental health; and
| ||||||
15 | WHEREAS, Historically disadvantaged groups face additional | ||||||
16 | barriers to treatment for substance use and opioid use | ||||||
17 | disorders, such as a lack of affordable therapy, stigma, and | ||||||
18 | unequal access to mental health treatment; mental health | ||||||
19 | equity should focus on access to quality and appropriate | ||||||
20 | healthcare services; and
| ||||||
21 | WHEREAS, The purpose of many federal programs is to |
| |||||||
| |||||||
1 | provide resources to states for increasing access to | ||||||
2 | FDA-approved medications for the treatment of substance use | ||||||
3 | and opioid use disorder and for supporting the continuum of | ||||||
4 | prevention, harm reduction, treatment, and recovery support | ||||||
5 | services for opioid use disorder and other substance use | ||||||
6 | disorders; and
| ||||||
7 | WHEREAS, A prescription digital therapeutic, which | ||||||
8 | utilizes both cognitive behavioral therapy and contingency | ||||||
9 | management in the product to treat substance use disorder or | ||||||
10 | opioid use disorder, is approved, cleared, or classified by | ||||||
11 | the Food and Drug Administration under section 510(k), 513(f), | ||||||
12 | or 515 of the Federal Food, Drug, and Cosmetic Act and requires | ||||||
13 | a prescription under section 801.109 of title 21 of the Code of | ||||||
14 | Federal Regulations (or any successor regulation); and
| ||||||
15 | WHEREAS, Prescription digital therapeutics have the | ||||||
16 | potential to significantly improve health care delivery to | ||||||
17 | underserved populations because they transcend care access | ||||||
18 | limitations due to geography, socioeconomic status, trust of | ||||||
19 | traditional institutions, and more; and
| ||||||
20 | WHEREAS, Clinical studies have shown significantly greater | ||||||
21 | odds of stimulant and opioid abstinence during treatment if | ||||||
22 | treatment as usual is combined with an FDA-authorized PDT that | ||||||
23 | has both cognitive behavioral therapy and contingency |
| |||||||
| |||||||
1 | management; and
| ||||||
2 | WHEREAS, A 2018 study demonstrated that when a Community | ||||||
3 | Reinforcement Approach and Contingency Management are | ||||||
4 | administered together then a patient is 2.84 times more likely | ||||||
5 | to remain abstinent at the end of the treatment than those in | ||||||
6 | other programs; and
| ||||||
7 | WHEREAS, The White House's Office of National Drug Control | ||||||
8 | Policy recently released its 2022 National Drug Control | ||||||
9 | Strategy document; specifically, the document points to | ||||||
10 | prescription digital therapeutics and how these tools could | ||||||
11 | help increase services for a wide array of patients; and
| ||||||
12 | WHEREAS, Federally-funded programs help many states to | ||||||
13 | fund access to FDA-authorized PDTs for patients and providers; | ||||||
14 | therefore, be it
| ||||||
15 | RESOLVED, BY THE HOUSE OF REPRESENTATIVES OF THE ONE | ||||||
16 | HUNDRED THIRD GENERAL ASSEMBLY OF THE STATE OF ILLINOIS, that | ||||||
17 | we urge the Department of Human Services and the Governor's | ||||||
18 | Opioid Overdose Prevention and Recovery Steering Committee to | ||||||
19 | closely consider funding FDA-authorized PDTs to help patients | ||||||
20 | who are struggling with substance use and opioid use | ||||||
21 | disorders; and be it further
|
| |||||||
| |||||||
1 | RESOLVED, That a suitable copy of this resolution be | ||||||
2 | delivered to the Secretary of the Illinois Department of Human | ||||||
3 | Services.
|